NEW YORK — Tabula Rasa HealthCare said on Thursday that it has signed an agreement to combine its MedWise medication decision support software with OneOme's RightMed pharmacogenomics test.
Financial and other terms of the deal were not disclosed.
MedWise reviews a patient's medication regimen in order to identify accumulative multi-drug interactions and support treatment decision-making. RightMed analyzes 27 genes in order to predict how a patient will respond to a particular drug.
"The additive power of combining OneOme's RightMed Test with … MedWise technology will bring more precision pharmacotherapy opportunities to our partners in programs of all-inclusive care for the elderly organizations and beyond," Tabula Rasa Chairman and CEO Calvin Knowlton said in a statement.
In mid-2019, Moorestown, New Jersey-based Tabula Rasa formed a pharmacogenomics delivery and analytics alliance with CQuentia. The previous year, Minneapolis-based OneOme received approval from the New York State Department of Health for RightMed.